A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia

Srinivas K. Tantravahi, Philippe Szankasi, Jamshid S. Khorashad, Kim Hien Dao, Tibor Kovacsovics, Todd W. Kelley, Michael W. Deininger

Research output: Contribution to journal › Letter › peer-review

18 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia'. Together they form a unique fingerprint.